✦ LIBER ✦

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

✍ Scribed by D. Amadori; C. Milandri; G. Comella; S. Saracchini; S. Salvagni; C. Barone; R. Bordonaro; V. Gebbia; A. Barbato; P. Serra; D. Gattuso; O. Nanni; B. Baconnet; G. Gasparini

Book ID: 116430769
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 226 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.05.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Non-pegylated liposomal doxorubicin comb

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

✍ S. Del Barco; R. Colomer; L. Calvo; I. Tusquets; E. Adrover; P. Sánchez; J. Rifà 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 220 KB

A multicentre Phase II study of non-pegy

A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer

✍ M. Venturini; C. Bighin; F. Puglisi; N. Olmeo; E. Aitini; G. Colucci; O. Garrone 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 262 KB

Pegylated liposomal doxorubicin and tras

Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial

✍ Elmar Stickeler; Maximilian Klar; Dirk Watermann; Annette Geibel; Martha Földi; 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 276 KB

Trastuzumab plus docetaxel with or witho

Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study

✍ A. Wardlev; A. Anton-Torres; X. Pivot; F. Morales-Vasquez; L. Zetina; M. de Fati 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

5068 Cardiac safety of non-pegylated lip

5068 Cardiac safety of non-pegylated liposomal doxorubicin in combination with docetaxel as 1st line treatment in locally advanced or metastatic HER2 negative breast cancer (MYOTAX study)

✍ L.J.C. van Warmerdam; P.P. Schiphorst; P. Nieboer; M.W. Dercksen; J.F.M. Pruijt; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Phase II Trial of Weekly Docetaxel, Vino

Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

✍ Jeffrey R. Infante; Denise A. Yardley; Howard A. Burris III; F. Anthony Greco; C 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 120 KB